376 related articles for article (PubMed ID: 9713009)
21. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis.
Whitehead A; Conway SP; Etherington C; Caldwell NA; Setchfield N; Bogle S
Eur Respir J; 2002 Feb; 19(2):303-9. PubMed ID: 11866010
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
[TBL] [Abstract][Full Text] [Related]
23. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
24. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
[TBL] [Abstract][Full Text] [Related]
25. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
26. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Ryan G; Jahnke N; Remmington T
Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
[TBL] [Abstract][Full Text] [Related]
27. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
Strandvik B; Malmborg AS; Alfredson H; Ericsson A
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
[TBL] [Abstract][Full Text] [Related]
28. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
[TBL] [Abstract][Full Text] [Related]
30. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.
Gold R; Overmeyer A; Knie B; Fleming PC; Levison H
Pediatr Infect Dis; 1985; 4(2):172-7. PubMed ID: 3885181
[TBL] [Abstract][Full Text] [Related]
31. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
McCrae WM; Raeburn JA; Hanson EJ
J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
[TBL] [Abstract][Full Text] [Related]
34. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
Adeboyeku D; Jones AL; Hodson ME
J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
[TBL] [Abstract][Full Text] [Related]
35. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
Richard DA; Nousia-Arvanitakis S; Sollich V; Hampel BJ; Sommerauer B; Schaad UB
Pediatr Infect Dis J; 1997 Jun; 16(6):572-8. PubMed ID: 9194107
[TBL] [Abstract][Full Text] [Related]
36. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
Barras MA; Serisier D; Hennig S; Jess K; Norris RL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
[TBL] [Abstract][Full Text] [Related]
37. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
[TBL] [Abstract][Full Text] [Related]
38. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
Wang X; Koehne-Voss S; Anumolu SS; Yu J
J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
[TBL] [Abstract][Full Text] [Related]
39. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
[TBL] [Abstract][Full Text] [Related]
40. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
Parry MF; Neu HC
J Infect Dis; 1976 Aug; 134 Suppl():S194-7. PubMed ID: 823276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
